Business Context and Reporting Period
Company: Palisade Bio, Inc. (PALI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Palisade Bio is a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 (PDE4) inhibitor prodrugs for inflammatory bowel disease (IBD). Its lead asset, PALI-2108, is designed for targeted delivery to the terminal ileum and colon to treat ulcerative colitis (UC) and Crohn's disease (CD). The company has no approved products and has never generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16.8) million | $(14.4) million |
| Operating Expenses | $18.1 million | $14.9 million |
| Research & Development (R&D) | $10.2 million | $9.1 million |
| General & Administrative (G&A) | $7.9 million | $5.8 million |
| Cash Used in Operating Activities | $(10.8) million | $(12.2) million |
| Cash Provided by Financing Activities | $134.4 million | $9.6 million |
| Cash, Cash Equivalents & Restricted Cash (Year End) | $133.4 million | $9.8 million |
| Debt | $0.1 million (Insurance financing) | $0.1 million |
Note: All figures in millions unless otherwise noted. The company reported no revenue for either period.
Material Changes vs. Prior Period
- Capital Raise: In October 2025, the company completed an underwritten public offering raising approximately $127.6 million in net proceeds. This significantly increased cash reserves from $9.8 million in 2024 to $133.4 million in 2025.
- Expense Growth: Total operating expenses increased 22% year-over-year. R&D expenses rose 12% due to the commencement of the Phase 1 clinical trial of PALI-2108 and increased headcount. G&A expenses rose 36%, driven by higher stock-based compensation and professional fees.
- Net Loss: Net loss increased by 16% to $16.8 million, primarily due to higher operating expenses, partially offset by increased interest and dividend income ($1.3 million in 2025 vs. $0.4 million in 2024).
- Warrant Inducement: In July 2025, the company executed a warrant inducement transaction generating $3.4 million in net proceeds.
Guidance, Outlook, and Risks
Outlook and Milestones
- Clinical Progress: The Phase 1 clinical trial of PALI-2108 in Canada met primary endpoints for safety, tolerability, and pharmacokinetics. Positive results were announced for healthy volunteers and a UC patient cohort. An exploratory Phase 1b cohort in Fibrostenotic Crohn's Disease (FSCD) began dosing in October 2025.
- Future Trials: The company anticipates submitting Investigational New Drug (IND) applications to the FDA for a Phase 2 UC study in Q2 2026 and a Phase 2 CD study in H2 2026.
- Liquidity: Management believes current cash resources are sufficient to fund operations through major clinical milestones, including Phase 2 primary efficacy readouts for UC (expected H2 2027) and CD (expected 2028).
Key Risks and Contingencies
- Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to a lack of segregation of duties and formalized processes for journal entries and reconciliations. This weakness remains unremediated as of December 31, 2025.
- Regulatory Uncertainty: The FDA may not accept data from the Canadian Phase 1 trial, potentially requiring additional U.S. trials. There is no guarantee of regulatory approval for PALI-2108.
- Third-Party Dependence: The company relies on third-party CROs and CMOs for clinical trials and manufacturing. It depends on two qualified suppliers for the active pharmaceutical ingredient (API) for PALI-2108.
- Intellectual Property: Rights to PALI-2108 are licensed from Giiant Pharma Inc. Termination of this agreement or failure to meet obligations could halt development.
- Government Shutdowns: Recent and potential future U.S. government shutdowns could delay FDA reviews and impact access to capital markets.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $133.4 million cash balance against the projected burn rate to reach Phase 2 readouts in 2027-2028.
- Internal Controls: Monitor the status of remediation efforts for the material weakness in internal controls over financial reporting.
- Regulatory Acceptance: Confirm FDA acceptance of Canadian Phase 1 data for the upcoming IND submission in 2026.
- Supply Chain: Assess the stability of the two API suppliers and the impact of potential trade restrictions (e.g., BIOSECURE Act) on Chinese manufacturing partners.
- Dilution: Review the impact of outstanding warrants (64 million outstanding) and pre-funded warrants on future share count and dilution.